Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sean Wilkinson

Orthopaedic Surgery Newton, NJ Doctor of Osteopathy

NPI 1649615626 CMS profile 837054

280 Newton Sparta Rd Ste 4, Newton, NJ 07860

Open in the dashboard

General payments

$6,503

38 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Sean Wilkinson of Newton, NJ is reported in the CMS Open Payments database as having received $6,503 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $74 1
2023 General $296 3
2022 General $193 3
2021 General $416 6
2020 General $123 2
2019 General $5,402 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Wilkinson
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Sean Wilkinson were reported at $0. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Sean Wilkinson Orthopaedic Surgery median Middle half National median
2019 $5,402 $644 $140–$2,844 $163
2020 $123 $312 $75–$1,860 $114
2021 $416 $520 $117–$2,495 $132
2022 $193 $598 $128–$2,731 $149
2023 $296 $461 $128–$2,264 $160
2024 $74 $497 $134–$2,475 $164
2025 $0 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Arthrex, Inc. $4,981 18 payments
  2. Zimmer Biomet Holdings, Inc. $735 9 payments
  3. Smith+Nephew, Inc. $392 4 payments
  4. DePuy Synthes Sales Inc. $168 3 payments
  5. Stryker Corporation $161 1 payment
  6. Fidia Pharma USA Inc. $65 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $3,816 4 payments
  2. Food and Beverage $1,540 25 payments
  3. Travel and Lodging $1,147 9 payments
Products named General payments · program years 2019–2024
  1. Comprehensive Primary Stem $375 5 payments
  2. HIPMAP $161 1 payment
  3. LENS 4K $150 1 payment
  4. Bioinductive Implant with Arthroscopic Delivery System - Medium $147 1 payment
  5. ATTUNE $141 1 payment
  6. Accelero-None $100 1 payment
  7. Tapestry $74 1 payment
  8. HYMOVIS $65 3 payments
  9. Trabecular Metal (TM) Shoulder $61 1 payment
  10. HEALICOIL $55 1 payment
  11. Other $115 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

612

Median for Orthopedic Surgery: 203

Drug cost

$3,678

Median for Orthopedic Surgery: $1,433

Branded share of claims

6.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 112 $1,481
Diclofenac Sodium Generic 16 $423
Methylprednisolone Generic 69 $372
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 38 $333
Prednisone Generic 102 $287
Gabapentin Generic 47 $238
Cyclobenzaprine Hcl Generic 63 $225
Meloxicam Generic 93 $128
Naproxen Generic 31 $115
Tramadol Hcl Generic 25 $48

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$245,355

Of which drugs: $50,907

Medicare patients

584

Average age 75

Services billed

9,235

340 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 36%
Diabetes 27%
Chronic kidney disease 25%
Atrial fibrillation 20%
Depression 20%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 55 5,154 $36,003
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 276 518 $2,683

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record